218 related articles for article (PubMed ID: 33317909)
1. The psychosexual effects of risk-reducing bilateral salpingo-oophorectomy in female BRCA1/2 mutation carriers: A systematic review of qualitative studies.
Hickey I; Jha S; Wyld L
Gynecol Oncol; 2021 Mar; 160(3):763-770. PubMed ID: 33317909
[TBL] [Abstract][Full Text] [Related]
2. Risk-Reducing Bilateral Salpingo-Oophorectomy for BRCA Mutation Carriers and Hormonal Replacement Therapy: If It Should Rain, Better a Drizzle than a Storm.
Gasparri ML; Taghavi K; Fiacco E; Zuber V; Di Micco R; Gazzetta G; Valentini A; Mueller MD; Papadia A; Gentilini OD
Medicina (Kaunas); 2019 Jul; 55(8):. PubMed ID: 31362334
[TBL] [Abstract][Full Text] [Related]
3. The impact of risk reducing bilateral salpingo-oophorectomy on sexual function in BRCA1/2 mutation carriers and women with Lynch syndrome: A systematic review and meta-analysis.
Kershaw V; Hickey I; Wyld L; Jha S
Eur J Obstet Gynecol Reprod Biol; 2021 Oct; 265():7-17. PubMed ID: 34416580
[TBL] [Abstract][Full Text] [Related]
4. Risk-reducing salpingo-oophorectomy among diverse patients with
Lamacki AJ; Spychalska S; Maga T; Balay L; Lugo Santiago N; Hoskins K; Richardson K; Class QA; MacLaughlan David S
BMJ Open; 2024 Jun; 14(6):e082608. PubMed ID: 38889943
[TBL] [Abstract][Full Text] [Related]
5. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
6. Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
Hall E; Finch A; Jacobson M; Rosen B; Metcalfe K; Sun P; Narod SA; Kotsopoulos J
Gynecol Oncol; 2019 Jan; 152(1):145-150. PubMed ID: 30414741
[TBL] [Abstract][Full Text] [Related]
7. Exploring factors that impact uptake of risk-reducing bilateral salpingo-oophorectomy (RRBSO) in high-risk women.
Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
Menopause; 2020 Jan; 27(1):26-32. PubMed ID: 31613831
[TBL] [Abstract][Full Text] [Related]
8. Risk-reducing bilateral salpingo-oophorectomy and sexual health: a qualitative study.
Brotto LA; Branco N; Dunkley C; McCullum M; McAlpine JN
J Obstet Gynaecol Can; 2012 Feb; 34(2):172-178. PubMed ID: 22340066
[TBL] [Abstract][Full Text] [Related]
9. Risk-reducing salpingo-oophorectomy and breast cancer incidence among Jewish BRCA1/BRCA2-mutation carriers-an Israeli matched-pair study.
Perri T; Levin G; Naor-Revel S; Eliassi-Revivo P; Lifshitz D; Friedman E; Korach J
Int J Gynaecol Obstet; 2022 May; 157(2):431-436. PubMed ID: 34324701
[TBL] [Abstract][Full Text] [Related]
10. Specialist oncological surgery for removal of the ovaries and fallopian tubes in BRCA1 and BRCA2 pathogenic variant carriers may reduce primary peritoneal cancer risk to very low levels.
Crosbie EJ; Flaum N; Harkness EF; Clayton RD; Holland C; Martin-Hirsch P; Wood N; Keating P; Woodward ER; Lalloo F; Donnai P; Edmondson RJ; Evans DG
Int J Cancer; 2021 Mar; 148(5):1155-1163. PubMed ID: 33152107
[TBL] [Abstract][Full Text] [Related]
11. Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits.
Gordhandas S; Norquist BM; Pennington KP; Yung RL; Laya MB; Swisher EM
Gynecol Oncol; 2019 Apr; 153(1):192-200. PubMed ID: 30661763
[TBL] [Abstract][Full Text] [Related]
12. What information do healthcare professionals need to inform premenopausal women about risk-reducing salpingo-oophorectomy?
Hickey M; Rio I; Trainer A; Marino JL; Wrede CD; Peate M
Menopause; 2020 Jan; 27(1):20-25. PubMed ID: 31567874
[TBL] [Abstract][Full Text] [Related]
13. Hormone replacement therapy after prophylactic risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 and BRCA2 mutation carriers: A meta-analysis.
Marchetti C; De Felice F; Boccia S; Sassu C; Di Donato V; Perniola G; Palaia I; Monti M; Muzii L; Tombolini V; Benedetti Panici P
Crit Rev Oncol Hematol; 2018 Dec; 132():111-115. PubMed ID: 30447915
[TBL] [Abstract][Full Text] [Related]
14. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
15. Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial.
van Driel C; de Bock GH; Schroevers MJ; Mourits MJ
BJOG; 2019 Feb; 126(3):402-411. PubMed ID: 30222235
[TBL] [Abstract][Full Text] [Related]
16. Menopausal hormone therapy for BRCA-mutation carriers: attitudes of Israeli healthcare providers before and after a brief educational intervention.
Perri T; Farhadian Y; Friedman E; Korach J
Menopause; 2020 Jan; 27(1):82-87. PubMed ID: 31688415
[TBL] [Abstract][Full Text] [Related]
17. Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: An evidence-based approach on what women should know.
De Felice F; Marchetti C; Boccia SM; Romito A; Sassu CM; Porpora MG; Muzii L; Tombolini V; Benedetti Panici P
Cancer Treat Rev; 2017 Dec; 61():1-5. PubMed ID: 29028552
[TBL] [Abstract][Full Text] [Related]
18. Risk of cardiovascular disease among women carrying BRCA mutations after risk-reducing bilateral salpingo-oophorectomy: A population-based study.
do Valle HA; Kaur P; Kwon JS; Cheifetz R; Dawson L; Hanley GE
Gynecol Oncol; 2021 Sep; 162(3):707-714. PubMed ID: 34217543
[TBL] [Abstract][Full Text] [Related]
19. Bone health after RRBSO among
do Valle HA; Kaur P; Kwon JS; Cheifetz R; Dawson L; Hanley GE
J Gynecol Oncol; 2022 Jul; 33(4):e51. PubMed ID: 35557034
[TBL] [Abstract][Full Text] [Related]
20. Hormone therapy after prophylactic risk-reducing bilateral salpingo-oophorectomy in women who have BRCA gene mutation.
Guidozzi F
Climacteric; 2016 Oct; 19(5):419-22. PubMed ID: 27426853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
